NCT02054208View on ClinicalTrials.gov

Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL

human umbilical cord blood derived mesenchymal stem cells

"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"

OTHER

Normal saline 2mL

Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Medipost Co Ltd.

INDUSTRY

NCT02054208 - Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter